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Abstract 
Purpose – The prevalence of obesity is increasing rapidly in older adults. Information 
is required about what interventions are effective in reducing obesity and influencing 
health outcomes in this age group. 
Design – Systematic review and meta-analysis 
Data sources – Thirteen databases were searched, earliest date 1966 to December 
2008, including Medline, CINAHL, PsycInfo, the Cochrane database and EMBASE.   
Study selection – We included studies with participants’ mean age ≥ 60y, mean body 
mass index ≥ 30 kg/m 2
Data extraction – Nine eligible trials were included. Study interventions targeted 
diet, physical activity and mixed approaches. Populations included patients with 
coronary artery disease, diabetes mellitus and osteoarthritis.  
, with outcomes at a minimum of 1 year. Data were 
independently extracted by two reviewers and differences resolved by consensus.  
Results - Meta-analysis (7 studies) demonstrated a modest but significant weight loss 
of 3.0 kg (95% CI 5.1 to 0.9) at 1 year. Total cholesterol (4 studies) did not show a 
significant change; -0.36 mmol/L (95% CI -0.75 to 0.04). There was no significant 
change in HDL, LDL or triglycerides. In one study recurrence of hypertension or 
cardiovascular events were significantly reduced (hazard ratio 0.65, 95% CI 0.50 to 
0.85). Six minute walk test did not change significantly in one study. Health related 
quality of life significantly improved in one study but did not improve in a second 
study. 
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Conclusions - Although modest weight reductions were observed, there is a lack of 
high quality evidence to support the efficacy of weight loss programmes in older 
people. 
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Key Points: 
• Obesity levels are rising in the over 60s. 
• Weight loss interventions in older people has not been well studied. 
• Weight loss programmes have a modest effect in those aged 60 and over. 
• There is a dearth of high-quality evidence for obesity interventions in this age 
group. 
• Further trial evidence about effects of intentional weight loss is needed, 
particularly for older old people, examining effects on markers of vascular risk, 
quality of life, physical function, cardiovascular events and death. 
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Introduction 
 
Obesity is recognised as a major health problem amongst children, younger adults and 
middle-aged adults in the developed world and increasingly in rapidly industrialising 
countries[1]. The prevalence of obesity [body mass index (BMI) ≥30kg/m 2
 
] in the US 
is currently between 30 and 35% in both middle aged adults (40-59 years) and in 
older adults (>60 years)[2]. Obesity in older adults is also increasing rapidly in other 
industrialised countries; England has seen a rapid increase in the number of older 
adults with obesity – rising from 16% of women and 15% of men aged 75 and over in 
1994[3] to 27% and 18% respectively in 2006. In younger people, obesity is well 
known to be associated with adverse cardiovascular outcomes, osteoarthritis, type 2 
diabetes mellitus and reduced exercise capacity[4]. All of these problems are 
prevalent in older people, and contribute to the high burden of disease and functional 
impairment. 
Compared to younger people, there appears to have been very little research aimed at 
reducing obesity in older adults. There is evidence that modest degrees of overweight 
(BMI 25-29.9 kg/m2) are not associated with increased mortality in older people[5]; 
indeed the optimum BMI for older adults is higher than for younger people. However, 
a recent meta-analysis of cohort studies found an association between BMI ≥30kg/m 2 
and mortality in older people (RR 1.10, 95% CI 1.06-1.13)[5]. Similar findings are 
evident when using more detailed anthropometric measures to circumvent the 
inaccuracies of BMI measurement in older people; older males with increased waist 
circumference showed increased mortality after adjustment for mid-arm muscle 
circumference[6]. The effects of obesity may be reversible even in older people; a 
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large cohort study suggested that perceived intentional weight loss confers a 
significant reduction in all-cause mortality in males aged 56-75 years[7].  
 
Losing weight is difficult, and interventions that work in younger adults cannot be 
assumed to translate successfully into an older population, where low muscle mass 
and consequent physical frailty, osteoporosis, comorbid disease and cultural 
differences may increase risk and prevent benefits seen in younger people from 
translating into health gains in older people. It is likely that sustained weight loss is 
required to produce meaningful changes in health outcomes, particularly for 
cardiovascular disease. We therefore systematically reviewed the evidence for 
interventions designed to produce sustained weight loss in obese older adults to 
inform current practice. 
 
Methods 
 
We conducted a systematic review using a prespecified protocol, devised according to 
the guidelines of the Cochrane Collaboration. We included randomised controlled 
trials in which weight loss was a primary aim of the intervention, for which follow-up 
data at a minimum of one year were available, in which the mean age of groups was 
60 years or greater and the mean baseline BMI was ≥30 kg/m 2
 
 . We included trials 
with placebo or no intervention for the control group, and trials comparing active 
intervention groups. No language restrictions were used. We excluded studies in 
which weight loss was a coincidental change produced by another type of 
intervention. 
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Data sources and search strategy 
We searched 13 electronic databases, earliest date 1966 until 2001[8], five electronic 
databases from 2001 - December 2008 (Medline, CINAHL, Psycinfo, the Cochrane 
database and EMBASE), and handsearched four obesity and geriatrics journals. Full 
details of the search strategies have been published previously[6]. We used weight 
loss, weight maintenance and obesity related terms customised to each database.  
 
Outcomes 
We sought the following outcomes: weight, BMI, total cholesterol, HDL cholesterol, 
LDL cholesterol, triglycerides, fasting glucose, glycosylated haemoglobin (HbA1c), 
blood pressure. We also sought information on deaths, hospitalisations, morbidity, 
quality of life, measures of physical function and exercise capacity, and dropouts. We 
collected data on age, sex, social class, smoking status, dwelling place, disease state 
and source of trial funding. 
 
Data extraction and quality assessment 
Data were abstracted by two researchers independently, and discrepancies were 
resolved by consensus. Clarification of data was obtained by correspondence with 
trialists. Values for standard deviations of change in weight, blood pressure and lipids 
were imputed if not available from trial reports, based on previously published 
algorithms[8]. Where BMI was recorded but not weight, we imputed weight based on 
height data from the NHANES III dataset[9]. Study quality was assessed by two 
reviewers independently, and disagreements resolved by consensus. Allocation 
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concealment, description of dropouts, availability of intention to treat analysis, 
blinding and baseline comparability of groups were assessed. 
 
Data synthesis and analysis 
Meta-analysis was undertaken where results could be quantitatively combined, using 
RevMan 4.2 software (Cochrane Collaboration). I2
 
 tests for heterogeneity across 
analyses were performed, and possible sources of heterogeneity were explored. 
Random effects models were used for all analyses. 
Results 
 
Selection of trials 
Reports of 649 potentially eligible studies were retrieved for further scrutiny (Figure 
1). The vast majority were ineligible for inclusion; reasons included mean age of 
groups <60 years, weight reduction not a primary aim of the study; design other than 
randomised controlled trial; mean baseline BMI <30 kg/m2
 
, and follow-up less than 
12 months.  
Description of the interventions 
Table 1 gives details of the nine studies included in the review. With one 
exception[10] the included trials were all carried out in the USA; most studies 
targeted patients with a specific disease entity (diabetes mellitus, coronary artery 
disease, osteoarthritis). Studies were a mixture of single centre and multicentre trials, 
with some interventions conducted in community or primary care settings, and some 
in secondary care settings. All studies examined patients who were living in the 
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community rather than in institutional settings. Only two of the studies had a mean 
baseline BMI of >35kg/m2
 
 [11,12]. One trial[11] targeted black and white adults with 
diabetes living in medically underserved rural communities. 
All the trials provided dietary advice, with the exception of the PATH trial, which 
provided physical activity advice[17,18]. In two trials it was not clear whether this 
was low fat dietary advice[10,14]. Two trials did not report giving physical activity 
advice[10,15], and three trials provided facilities for undertaking physical 
activity[12,13,17,18].  
 
Study quality 
The quality of study design and reporting was variable. All studies reported random 
allocation and some studies specified intention to treat analysis in their protocols, but 
insufficient detail was given in most published reports to decide whether there was 
adequate allocation concealment. Only 2/9 studies clearly performed intention to treat 
analyses; insufficient detail was given in 3/9. Most studies gave numbers of 
withdrawals, but only four gave reasons for withdrawal or dropout. Baseline treatment 
and control groups were well balanced in all nine studies. Although it is usually not 
possible to blind patients to the intervention employed in weight loss studies, only one 
study clearly reported that the team in charge of patients’ usual care was blinded to 
the intervention, or that those measuring outcomes were blinded to treatment group.  
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Meta-analysis results 
Weight 
The overall weighted mean difference change in weight comparing intervention and 
control groups at 12 months was -3.0 kg (95% CI -5.1 to -0.9, P=.005); results are 
displayed in Figure 2. Significant statistical heterogeneity was evident (I2
 
=89%; 
P<.001). Post hoc grouping of the trials according to the type of intervention appears 
to suggest that trials which provided physical activity advice with dietary advice 
appeared to provide greater weight loss. Omission of the two studies for which weight 
change was extrapolated from BMI change[15,16] gave a change in weight of -3.3 kg 
(95% CI -5.8 to -0.8, P=.009). 
Post hoc subgroup analysis was also performed grouping studies into those with a 
defined weight loss or calorie restriction and those without such a goal. Studies with a 
clearly defined weight loss goal[10-12,14] showed a change in weight of -4.0 kg 
(95% CI -7.3 to -0.7), compared with -1.3 kg (95% CI -2.9 to 0.3, P<.001 for 
difference) in those without a defined goal[15-17]. 
 
Data from the ADAPT study were not incorporated into the meta-analysis, as data 
were collected at 18 months from randomisation. This study showed a 12.8 kg fall in 
mean weight in the intervention group, compared with a 2.3 kg fall in the control 
group. (difference -10.5 kg, 95% CI -16.4 to -4.6). Toobert[16] reported weight 
change at 24 months, with a reduction of 2.8 kg (95% CI -7.8 to 2.2) compared with 
the control group; somewhat smaller than the 5.4 kg difference seen at 12 months. 
TONE[14] reported weight outcomes at 18, 24 and 30 months, showing a reduction 
compared with the control group of -4.6 kg (95% CI -5.6 to -3.6) at 18 months, -4.5 
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kg (95% CI -5.6 to -3.4) at 24 months, and -4.9kg (-6.5 to -3.4) at 30 months. Results 
from the DPP study[19] 
 
were also not incorporated into the meta-analysis as the 
analysis was performed over 3.2 years rather than at a discrete timepoint; the weight-
loss intervention group lost a mean of 6.4 kg over the study, compared to a 0.2 kg 
reduction in the placebo arm (P<.001) 
Lipids 
Data on change in total cholesterol at 12 months were available from four studies 
[10,15,16,18]; the overall weighted mean difference comparing intervention and 
control groups at one year was -0.36 mmol/L (95% CI -0.75 to 0.04, P=.08). Results 
are shown in Figure 3. Again, significant heterogeneity was detected (I2=77%, 
P=.004). Omitting one study[16] with an anomalous change in cholesterol in the 
control group at 12 months (data checked with author) gave an overall difference in 
change of -0.18 mmol/L (95% CI -0.44 to 0.08, P=.17) with lower heterogeneity 
(I2
 
=52%, p=0.13). This study also provided follow up data at 24 months; total 
cholesterol had risen by 0.31 mmol/L (95% CI -0.54 to 1.16) relative to the control 
group at this timepoint. 
Data on weighted mean difference changes in LDL and HDL cholesterol and 
triglycerides at 12 months were available from two studies[16,18]. The difference in 
change in LDL cholesterol between intervention and control groups was -0.04 
mmol/L (95% CI -0.25 to 0.18, P=.74, I2=0%), the difference in HDL cholesterol was 
0.04 mmol/L (95% CI -0.04 to 0.12, P=.37, I2=0%), and for triglycerides was 0.44 
mmol/L (95% CI -0.55 to 1.43, P=.39, I2
 
 =83%) 
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Blood pressure 
Blood pressure data were available from the TONE[14] study and one other smaller 
study[16]. In TONE, blood pressure medication withdrawal started 90 days after 
commencing the intervention. At this point, the weight loss group showed a reduction 
of 4.0/1.1 mmHg in blood pressure, whereas the usual care group showed a reduction 
of 0.8/0.8 mmHg (reported P<.001 for difference in systolic BP change), and 
antihypertensives could be stopped successfully in 87% of the usual care group 
compared with 93% of the weight loss group. Data for blood pressure one year or 
more after randomisation were not presented, but follow-up in TONE for recurrence 
of hypertension or cardiovascular events continued for a median period of 29 
months[14]. In the other study[16], there were no significant differences in either 
systolic or diastolic blood pressure between intervention and control groups at 12 
months or 24 months. 
 
Exercise capacity 
One study (ADAPT)[13] reported changes in six-minute walk distance at 18 months 
in patients with osteoarthritis. Distance walked in the control group fell by 4.7m, and 
increased by 9.7m in the intervention group; a statistically and clinically non-
significant difference[20]. In postmenopausal women[17], an exercise-based 
programme increased maximal oxygen uptake by 11.7% in the intervention group 
compared with 0.7% in the control group at 12 months (reported P<.001) 
 
Glycaemic control 
One study contained data on change in HbA1c at 12 months in patients with 
diabetes[15]. There was no difference in change between groups (mean HbA1c fell 
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from 7.9% to 7.8% in both groups, reported P=.42). The incidence of new onset 
diabetes in the DPP study[19] was considerably lower in the intervention group than 
in the control group (adjusted hazard ratio 0.50, 95%CI 0.29 to 0.89)  
 
Mortality, morbidity and hospitalisation 
Mortality and hospitalisations were not reported for any studies except TONE[14]. In 
the TONE study the reported hazard ratio for the primary end point (recurrence of 
hypertension or cardiovascular events) was 0.65 (95% CI, 0.50 to 0.85) for those 
randomised to weight loss alone compared with controls. One trial[16] reported a 
significant improvement in chest pain frequency, but not duration or severity in the 
intervention group over two years. 
 
Quality of life 
Two studies reported effects on the SF-36 quality of life measure. In one study[21], 
overall health-related quality of life improved by 3.6 points in the intervention group 
but worsened by 0.8 points in the control group at 12 months (reported P=.02). In the 
other[22], physical health scores improved by 0.8 points in the control group and 3.0 
points in the diet group; corresponding values for mental health scores were 0.8 and 
1.2 points respectively. None of these latter changes were reported as reaching 
statistical significance. 
 
Economic outcomes 
One trial of dietary advice estimated costs at US$137/participant[15]. 
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Discussion 
 
Key findings 
Our systematic review shows a modest but significant reduction in weight with weight 
loss interventions in older, obese people. No clinically significant improvement was 
seen in cholesterol levels, and data were insufficient to draw conclusions regarding 
the effect of weight loss interventions on other cardiovascular risk factors, exercise 
capacity, or quality of life. Results for weight loss and change in cholesterol showed 
significant heterogeneity, which may have related to whether physical activity was 
included in the intervention. Studies with explicit goals for weight reduction or calorie 
restriction produced greater weight loss than those without explicit goals. 
 
Two previous systematic reviews have been published examining weight reduction 
interventions in older people. In one, short-term interventions of six to twelve months 
were also included[23], but studies showing a reduction in weight of <2 kg were 
excluded, potentially biasing the results. This review concluded that clinically 
important benefits may be achievable in patients with diabetes, osteoarthritis and 
coronary artery disease. The second review[24] had similar inclusion criteria to the 
current review, but included fewer studies, and did not attempt to meta-analyse the 
results. A similar spread of weight reductions was noted compared with the current 
review. 
 
Strengths and weaknesses 
Although we believe that our search strategy has included all eligible papers, it is 
possible that unpublished studies exist that have not been included. Handsearching of 
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recent abstracts did not reveal any further studies however. The participants enrolled 
in the included studies did not appear to have a high burden of comorbid disease in 
comparison to many older people; baseline data regarding physical and psychosocial 
function were however lacking. Inadequate reporting and heterogenous outcome times 
and measures hampered our ability to combine data into meta-analysis; the results 
should therefore be treated with caution. Although anthropometric measures of 
adiposity may provide a more sensitive measure of response to interventions, these 
data were not available for most of the included studies. 
 
Study findings in context 
A variety of weight reduction approaches have been shown to be effective in younger 
patients, with a mean reduction of 5kg in weight at 12 months for low-fat diets[8]. In 
younger patients, epidemiological modelling suggests that intentional weight loss is 
associated with up to a 20% reduction in all-cause mortality in women[8]; this result 
was not seen in men with intentional weight loss. Concern exists that obesity may be 
protective against death in some diseases that are very common in older people, 
including coronary artery disease and heart failure – the so-called ‘obesity 
paradox’[23]. Our analysis is unable to shed further light on this issue; only the 
TONE study reported deaths and cardiovascular events, and numbers were too small 
to draw conclusions on death rates from this single study. Furthermore, it is probably 
unreasonable to expect to detect changes in markers of cardiovascular disease, 
exercise capacity and quality of life without first achieving a significant, sustained 
reduction in weight. 
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The paucity of trials conducted in older people is striking; indeed even those studies 
that we included had a mean age between 60 and 69 years. There is therefore virtually 
no evidence to guide practice in people older than this. Equally striking is the paucity 
of outcome data that addresses issues directly relevant to older people – exercise 
capacity, physical function and quality of life. Such data are essential if the overall 
impact of interventions on health status is to be determined, as opposed to a narrow 
effect on risk factors for disease. No studies of pharmacological interventions for 
weight loss in older people were found for inclusion in this review; results from the 
large SCOUT trial of sibutramine in high cardiovascular risk people should provide 
additional data in this area, although very few patients aged over 75 years were 
randomised[24].  
 
Future directions 
Trials of weight loss interventions in older people are badly needed. Such trials should 
incorporate approaches to behavioural modification grounded in psychological theory 
and tailored to older people, and need to take account of multiple comorbidities in 
older people. Trials will need to include much older people than previously, and 
should actively seek to include patients with extensive comorbidities. Baseline details 
need to include information on cognition, deprivation, physical function, social 
support and comorbid disease. Although weight, cardiovascular risk factors, and 
clinical outcomes such as cardiovascular events should be measured, patient-centred 
outcomes will also be needed[25]. Such an approach is necessary to ensure not only 
that the evidence base is relevant to typical older people with obesity, but that it can 
be seen to be relevant – by patients, healthcare providers and policymakers. 
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 Fig 1. Trial flow diagram 
 
 
Abstracts identified by search strategy (n=71677) 
(see reference 5 for details) 
 
        Not meeting inclusion 
        criteria on abstract / title 
Reports of studies retrieved for more  
detailed evaluation (n=649)* 
 
        Not meeting inclusion 
        criteria on review of paper 
Potentially appropriate studies to include (n=13) 
 
        Weight loss not  
        primary aim of study 
Studies included in systematic review (n=9) 
 
 
 
RCTs with usable outcome data:  
Weight or BMI (n=9),  
Blood pressure (n=1),  
Lipids (n=4) 
 
 
*Includes 400 reports of RCTs considered in previous HTA report[8]
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Table 1. Included studies 
 
 
Study Location N Comorbidity Sex Mean age 
(years) 
BMI 
(kg/m2
Intervention 
) 
Goal for 
weight loss 
or calorie 
restriction? 
Extractable 
outcomes 
Follow 
up 
(mths) 
% dropout 
at 12 mths 
Glasgow 
1997[15] 
USA; single 
secondary care 
centre (office 
based) 
206 Diabetes mellitus 62% 
female 
Ctrl: 63.1 
Int: 61.7 
Ctrl: 30.5 
Int: 30.4 
Ctrl: three and 12 month 
clinic appointment. 
Int: Counselling to remove 
barriers to dietary change; 
goal setting and problem 
solving at start to lower fat. 
Telephone follow up and 
repeat goal setting, follow-
up 3 monthly. 
No BMI, 
Cholesterol 
HbA1c 
12 16 
TONE 
1998[14] 
USA; 4 
academic 
secondary care 
centres plus 
community 
294 Hypertension, 
obesity 
55% 
female 
Ctrl: 66 
Int: 66 
Ctrl: 31.3 
Int: 31.0 
Ctrl: Talks unrelated to diet 
or sodium restriction 
Int: Aim 5-10% reduction 
in weight, social action 
theory, plus advice to 
increase physical activity. 4 
mths weekly intensive 
group and individual 
sessions; 3 mths fortnightly 
group meetings; then 
monthly group meetings   
Yes Weight 30 12 
Mengham 
1999[10] 
UK; single 
primary care 
centre 
75 Diabetes mellitus 55% 
female 
Ctrl: 63.5 
Int: 57.8 
Ctrl: 31.7 
Int: 31.4 
Ctrl: 15 min dietetic appt 
every 6 mths 
Int: Aim 10% reduction in 
BMI; fortnightly dietetic 
and group work sessions 
for 3 months. 
Yes Weight, 
cholesterol 
12 1 
Toobert 
2000[16] 
USA; 
community 
28 Postmenopausal, 
coronary heart 
disease 
100% 
female 
Ctrl 63 
Int: 64 
Ctrl: 32 
Int: 32 
Ctr: Usual care 
Int: Week long retreat; 
cooking classes, yoga, 
stress management, aerobic 
exercise, group support 
meetings. Twice weekly 
No BMI, BP, 
Cholesterol 
24 11 
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meetings for 15 months, 
then less frequent. 
Prescribed exercise 1hr 3 
times/week. Vegetarian diet 
and <10% fat 
ADAPT 
2002 
[13,22] 
USA; single 
academic 
centre and 
community 
316 Osteoarthritis 72% 
female 
Ctrl: 69 
Diet: 68 
Exercise: 
69 
Combined
: 68 
Ctrl: 34.5 
Diet: 34.4 
Exercise: 
34.6 
Combined: 
33.9 
Ctrl: Discussion groups 
Diet: 500 kcal/day 
reduction in intake, low fat, 
based on group dynamics 
and social cognitive theory 
initially weekly for 16 
weeks then 2 weekly, 
maintenance months 7-18. 
Exercise: supervised 1hr 
three days a week for 4 
months, then could be at 
home.  
Yes Weight, BMI, 
six min walk, 
quality of life 
18 20 
POWER 
2004[11] 
USA; two 
primary care 
centres 
187 Diabetes mellitus 79% 
female 
Ctrl: 62.4 
Int: 59.7 
Ctrl: 35.2 
Int: 37.6 
Ctrl: 1 session with 
nutritionist – aim 10% 
weight loss 
Int: Group and individual 
behavioural intervention 
with aim 10% weight loss, 
25% calories from fat, 150 
min/wk activity. Weekly 
for 4 mths, fortnightly for 2 
months, monthly for 6 
months. Advised to 
exercise 150min/week. 
Yes Weight 12 19 
PATH 
2005 
[17,18] 
USA; single 
secondary care 
centre plus 
community 
173 Postmenopausal 100% 
female 
Ctrl: 60.6 
Int: 60.7 
Ctrl: 30.5 
Int: 30.4 
Ctrl: Weekly stretching 
sessions 
Int: 3x/wk supervised 
aerobic exercise, aiming for 
70% VO2
No 
 max for 3 mths. 
Transition to home exercise 
4x/wk plus weekly 
supervised exercise. No 
dietary advice detailed. 
Weight, BMI 
Cholesterol 
Quality of life 
Maximal 
oxygen 
uptake 
12 2 
DPP 
2006[19] 
USA; multiple 
secondary care 
648 Impaired glucose 
tolerance 
51%  
female 
Combined
: 66.4 
Ctrl: 30.8 
Int: 30.5 
Ctrl: Annual 30 min talk 
about lifestyle adjustment 
Yes Weight, 
diabetes 
3.2 
years 
Unclear 
 25 
centres Int: Aim 7% weight loss. 
Low fat, low calorie diet. 1 
to 1 weekly lessons for 16 
weeks, followed by 
monthly group sessions. 
Goal of moderate intensity 
physical activity for 
150min/wk (unsupervised) 
incidence (mean) 
Villareal 
2008[12] 
USA; single 
secondary care 
centre 
27 Frail, >65 years 66% 
female 
Ctrl: 71.1 
Int: 69.4 
Ctrl: 39.0 
Int: 38.5 
Ctrl: Usual care. Instructed 
to avoid exercise or weight 
loss programmes 
Int: Weekly group nutrition 
and behaviour sessions for 
1yr. Goal 10% wt loss by 6 
mths; 500-750kcal deficit 
per day, <30% fat. Weight 
maintenance after 6 
months. 3x/wk supervised 
group exercise for 1yr; 75-
90% VO2
Yes 
 max endurance 
exercise, plus 65-80% 1 rep 
maximum resistance 
exercise 
Weight, 
markers of 
bone 
metabolism, 
bone mineral 
density 
12 11 
 26 
Fig 2. Meta-analysis of change in weight at 12 months 
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Fig 3. Meta-analysis of change in total cholesterol at 12 months 
 
 
